pimurutamab

Overview

Pimurutamab is an investigational anti-EGFR monoclonal antibody targeting EGFR. It is evaluated in nasopharyngeal carcinoma (NPC), where EGFR is overexpressed and drives tumor progression.

Evidence in the corpus

• Pimurutamab anti-EGFR monoclonal antibody listed alongside nimotuzumab as EGFR-targeting antibodies under evaluation in R/M NPC PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.